Genetically modified plant oils and the future of GM crops in Europe
It has long been known that European countries are falling well behind many other countries, such as the USA, China, Brazil and Argentina, in terms of their acceptance and cultivation of genetically modified crops.
According to the Organic Consumers Association, over 80% of soybeans grown in the USA are genetically modified and transgenic cotton is grown on more than 70% of cotton fields there. By contrast, only two varieties of GM crops have been approved for cultivation in the EU and only five countries grow even tiny amounts of them.
Somewhat surprisingly, Europe does import more than 30 million tonnes of GM grain for animal feed annually, and has not always been so opposed to GM crops. Many speculate that a loss of public confidence in science from the scare of mad cow disease in Britain and also the strength of the Green party in Germany during the development of GM technology led to Europe’s loss of faith in GM products.
But things may be about to change. In June of this year, EU environment ministers approved new rules that allow individual countries to make independent decisions on GM crops. Earlier this year in Britain, David Cameron commissioned a report into genetically modified crops. The Council of Science and Technology (CST) was asked to report on the latest evidence for and against GM technologies and was also asked to give advice on UK and EU regulation of the industry.
Leading scientists were called upon by the CST to make recommendations and contributions to the report; the scientists included individuals from the Sainsbury Laboratory, Rothamsted Research, Reading University and Cambridge University.
The inclusion of scientists from Rothamsted Research, the world’s longest running agricultural research establishment, in the production of this report is particularly relevant. This is because the charitable company has recently been granted permission by DEFRA to carry out a field trial in England over four years using GM Camelina plants. Camelina is a high yielding oilseed crop that has been grown in Europe since the Bronze Age. The field trial is currently the only trial of its kind in Britain and is funded by the Government through the Biotechnology and Biological Sciences Research Council (BBSRC.)
The plants have not been modified to show pest resistance, as might be expected, but have instead been modified to accumulate significant quantities of the omega-3 long chain polyunsaturated fatty acids (LC-PUFAs) EPA and DHA in their seeds. According to a World Health Organisation consultation, dietary omega-3 oils and specifically LC-PUFAs, currently obtained from some oily fish such as mackerel and salmon, have been linked to improved cognitive development and cardiovascular health.
Unfortunately, wild stocks and aquaculture are no longer able to provide a sustainable source of these oils. Fish are unable to produce these LC-PUFAs and instead accumulate them. In the wild this is from a diet of algae and in aquaculture, the source is actually other fish taken from the sea and used to feed the farmed fish. In practice, this means that 80% of the fish oil that is taken from the sea from fishing of wild populations is actually consumed by the aquaculture sector and is therefore unavailable to humans.
The scientists at Rothamsted Research have been working on this problem for fifteen years in the hope of developing a plant oil containing significant amounts of EPA and DHA for the aquaculture industry and even perhaps as a direct human source of these beneficial compounds through a cooking oil. They have managed to transfer key genes, which are found naturally in algae and involved in the synthesis of EPA and DHA, to the Camelina crop.
The Camelina seeds sown in mid-May of this year are due to be harvested and analysed for their EPA and DHA content in August and September and the process will be repeated for three further growing seasons. Johnathan Napier, the lead scientist of this project, commented: ‘Being able to carry out the field trial with our GM plants, means that we have reached a significant milestone in the delivery of our research programme.’ The scientists are convinced that the crops have the potential to make fish farming a more sustainable process by easing the pressure on wild fish populations.
Speaking more generally on the topic of GM crops, another Rothamsted researcher said: ‘GM is actually safer than most forms of breeding because we know exactly which properties are being implanted.’
The distinction between selective breeding and genetic modification, both of which are methods of crop mutation, is an interesting issue surrounding the GM debate and something that is connected to the points raised in the CST report. Beneforté or ‘super broccoli’ is a product that is already widely available in many UK supermarkets. It has been selectively bred to contain 2-3 times more glucoraphanin, which is a compound that could help to maintain cardiovascular health and reduce the risk of cancer. Therefore, in this case, the heath benefits of this artificially bred product are seen to outweigh any risks that might be associated with this genome manipulation.
If the Camelina field trial and any further trials such as testing the success of using the modified plant oils in salmon farms are successful, it is not too difficult to see how steps towards the acceptance of GM crops with convincing health benefits could be taken over the next few years in Britain. It remains to be seen if similar possible advances towards increased use of this technology are taken throughout the rest of Europe.
Photograph: Matt Lavin on flickr

